The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Therapeutic Peptides Market Research Report 2024
Synopsis
Biosimilar therapeutic peptides are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease.
The global Biosimilar Therapeutic Peptides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Therapeutic Peptides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Therapeutic Peptides.
Report Scope
The Biosimilar Therapeutic Peptides market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Therapeutic Peptides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Therapeutic Peptides companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
li Lilly and Company
Sanofi
Takeda Pharmaceuticals
Teva Pharmaceuticals
Amgen
AstraZeneca
Novartis AG
Novo Nordisk
Segment by Type
Innovative
Generic
Segment by Application
Cancer
Cardiovascular
Central Nervous Systems
Metabolic Disorders
Gastrointestinal Disorders
Dermatology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Therapeutic Peptides companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Biosimilar therapeutic peptides are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease.
The global Biosimilar Therapeutic Peptides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Therapeutic Peptides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Therapeutic Peptides.
Report Scope
The Biosimilar Therapeutic Peptides market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Therapeutic Peptides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Therapeutic Peptides companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
li Lilly and Company
Sanofi
Takeda Pharmaceuticals
Teva Pharmaceuticals
Amgen
AstraZeneca
Novartis AG
Novo Nordisk
Segment by Type
Innovative
Generic
Segment by Application
Cancer
Cardiovascular
Central Nervous Systems
Metabolic Disorders
Gastrointestinal Disorders
Dermatology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar Therapeutic Peptides companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Therapeutic Peptides Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Innovative
1.2.3 Generic
1.3 Market by Application
1.3.1 Global Biosimilar Therapeutic Peptides Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 Central Nervous Systems
1.3.5 Metabolic Disorders
1.3.6 Gastrointestinal Disorders
1.3.7 Dermatology
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Therapeutic Peptides Market Perspective (2019-2030)
2.2 Biosimilar Therapeutic Peptides Growth Trends by Region
2.2.1 Global Biosimilar Therapeutic Peptides Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar Therapeutic Peptides Historic Market Size by Region (2019-2024)
2.2.3 Biosimilar Therapeutic Peptides Forecasted Market Size by Region (2025-2030)
2.3 Biosimilar Therapeutic Peptides Market Dynamics
2.3.1 Biosimilar Therapeutic Peptides Industry Trends
2.3.2 Biosimilar Therapeutic Peptides Market Drivers
2.3.3 Biosimilar Therapeutic Peptides Market Challenges
2.3.4 Biosimilar Therapeutic Peptides Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Therapeutic Peptides Players by Revenue
3.1.1 Global Top Biosimilar Therapeutic Peptides Players by Revenue (2019-2024)
3.1.2 Global Biosimilar Therapeutic Peptides Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilar Therapeutic Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Therapeutic Peptides Revenue
3.4 Global Biosimilar Therapeutic Peptides Market Concentration Ratio
3.4.1 Global Biosimilar Therapeutic Peptides Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Therapeutic Peptides Revenue in 2023
3.5 Biosimilar Therapeutic Peptides Key Players Head office and Area Served
3.6 Key Players Biosimilar Therapeutic Peptides Product Solution and Service
3.7 Date of Enter into Biosimilar Therapeutic Peptides Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Therapeutic Peptides Breakdown Data by Type
4.1 Global Biosimilar Therapeutic Peptides Historic Market Size by Type (2019-2024)
4.2 Global Biosimilar Therapeutic Peptides Forecasted Market Size by Type (2025-2030)
5 Biosimilar Therapeutic Peptides Breakdown Data by Application
5.1 Global Biosimilar Therapeutic Peptides Historic Market Size by Application (2019-2024)
5.2 Global Biosimilar Therapeutic Peptides Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar Therapeutic Peptides Market Size (2019-2030)
6.2 North America Biosimilar Therapeutic Peptides Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar Therapeutic Peptides Market Size by Country (2019-2024)
6.4 North America Biosimilar Therapeutic Peptides Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Therapeutic Peptides Market Size (2019-2030)
7.2 Europe Biosimilar Therapeutic Peptides Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar Therapeutic Peptides Market Size by Country (2019-2024)
7.4 Europe Biosimilar Therapeutic Peptides Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Therapeutic Peptides Market Size (2019-2030)
8.2 Asia-Pacific Biosimilar Therapeutic Peptides Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar Therapeutic Peptides Market Size (2019-2030)
9.2 Latin America Biosimilar Therapeutic Peptides Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar Therapeutic Peptides Market Size by Country (2019-2024)
9.4 Latin America Biosimilar Therapeutic Peptides Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Therapeutic Peptides Market Size (2019-2030)
10.2 Middle East & Africa Biosimilar Therapeutic Peptides Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Biosimilar Therapeutic Peptides Introduction
11.1.4 Pfizer Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Biosimilar Therapeutic Peptides Introduction
11.2.4 GlaxoSmithKline Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 li Lilly and Company
11.3.1 li Lilly and Company Company Detail
11.3.2 li Lilly and Company Business Overview
11.3.3 li Lilly and Company Biosimilar Therapeutic Peptides Introduction
11.3.4 li Lilly and Company Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.3.5 li Lilly and Company Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biosimilar Therapeutic Peptides Introduction
11.4.4 Sanofi Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Takeda Pharmaceuticals
11.5.1 Takeda Pharmaceuticals Company Detail
11.5.2 Takeda Pharmaceuticals Business Overview
11.5.3 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Introduction
11.5.4 Takeda Pharmaceuticals Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.5.5 Takeda Pharmaceuticals Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Introduction
11.6.4 Teva Pharmaceuticals Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Biosimilar Therapeutic Peptides Introduction
11.7.4 Amgen Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Biosimilar Therapeutic Peptides Introduction
11.8.4 AstraZeneca Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Detail
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Biosimilar Therapeutic Peptides Introduction
11.9.4 Novartis AG Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.9.5 Novartis AG Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Biosimilar Therapeutic Peptides Introduction
11.10.4 Novo Nordisk Revenue in Biosimilar Therapeutic Peptides Business (2019-2024)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Biosimilar Therapeutic Peptides Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Innovative
Table 3. Key Players of Generic
Table 4. Global Biosimilar Therapeutic Peptides Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Biosimilar Therapeutic Peptides Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Biosimilar Therapeutic Peptides Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Biosimilar Therapeutic Peptides Market Share by Region (2019-2024)
Table 8. Global Biosimilar Therapeutic Peptides Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Biosimilar Therapeutic Peptides Market Share by Region (2025-2030)
Table 10. Biosimilar Therapeutic Peptides Market Trends
Table 11. Biosimilar Therapeutic Peptides Market Drivers
Table 12. Biosimilar Therapeutic Peptides Market Challenges
Table 13. Biosimilar Therapeutic Peptides Market Restraints
Table 14. Global Biosimilar Therapeutic Peptides Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Biosimilar Therapeutic Peptides Market Share by Players (2019-2024)
Table 16. Global Top Biosimilar Therapeutic Peptides Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Therapeutic Peptides as of 2023)
Table 17. Ranking of Global Top Biosimilar Therapeutic Peptides Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Biosimilar Therapeutic Peptides Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Biosimilar Therapeutic Peptides Product Solution and Service
Table 21. Date of Enter into Biosimilar Therapeutic Peptides Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Biosimilar Therapeutic Peptides Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Biosimilar Therapeutic Peptides Revenue Market Share by Type (2019-2024)
Table 25. Global Biosimilar Therapeutic Peptides Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Biosimilar Therapeutic Peptides Revenue Market Share by Type (2025-2030)
Table 27. Global Biosimilar Therapeutic Peptides Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Biosimilar Therapeutic Peptides Revenue Market Share by Application (2019-2024)
Table 29. Global Biosimilar Therapeutic Peptides Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Biosimilar Therapeutic Peptides Revenue Market Share by Application (2025-2030)
Table 31. North America Biosimilar Therapeutic Peptides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Biosimilar Therapeutic Peptides Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Biosimilar Therapeutic Peptides Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Biosimilar Therapeutic Peptides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Biosimilar Therapeutic Peptides Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Biosimilar Therapeutic Peptides Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Biosimilar Therapeutic Peptides Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Biosimilar Therapeutic Peptides Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biosimilar Therapeutic Peptides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Biosimilar Therapeutic Peptides Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Biosimilar Therapeutic Peptides Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Biosimilar Therapeutic Peptides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Biosimilar Therapeutic Peptides Product
Table 49. Pfizer Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. GlaxoSmithKline Company Detail
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Biosimilar Therapeutic Peptides Product
Table 54. GlaxoSmithKline Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 55. GlaxoSmithKline Recent Development
Table 56. li Lilly and Company Company Detail
Table 57. li Lilly and Company Business Overview
Table 58. li Lilly and Company Biosimilar Therapeutic Peptides Product
Table 59. li Lilly and Company Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 60. li Lilly and Company Recent Development
Table 61. Sanofi Company Detail
Table 62. Sanofi Business Overview
Table 63. Sanofi Biosimilar Therapeutic Peptides Product
Table 64. Sanofi Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 65. Sanofi Recent Development
Table 66. Takeda Pharmaceuticals Company Detail
Table 67. Takeda Pharmaceuticals Business Overview
Table 68. Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Product
Table 69. Takeda Pharmaceuticals Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 70. Takeda Pharmaceuticals Recent Development
Table 71. Teva Pharmaceuticals Company Detail
Table 72. Teva Pharmaceuticals Business Overview
Table 73. Teva Pharmaceuticals Biosimilar Therapeutic Peptides Product
Table 74. Teva Pharmaceuticals Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 75. Teva Pharmaceuticals Recent Development
Table 76. Amgen Company Detail
Table 77. Amgen Business Overview
Table 78. Amgen Biosimilar Therapeutic Peptides Product
Table 79. Amgen Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 80. Amgen Recent Development
Table 81. AstraZeneca Company Detail
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Biosimilar Therapeutic Peptides Product
Table 84. AstraZeneca Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 85. AstraZeneca Recent Development
Table 86. Novartis AG Company Detail
Table 87. Novartis AG Business Overview
Table 88. Novartis AG Biosimilar Therapeutic Peptides Product
Table 89. Novartis AG Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 90. Novartis AG Recent Development
Table 91. Novo Nordisk Company Detail
Table 92. Novo Nordisk Business Overview
Table 93. Novo Nordisk Biosimilar Therapeutic Peptides Product
Table 94. Novo Nordisk Revenue in Biosimilar Therapeutic Peptides Business (2019-2024) & (US$ Million)
Table 95. Novo Nordisk Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biosimilar Therapeutic Peptides Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Biosimilar Therapeutic Peptides Market Share by Type: 2023 VS 2030
Figure 3. Innovative Features
Figure 4. Generic Features
Figure 5. Global Biosimilar Therapeutic Peptides Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Biosimilar Therapeutic Peptides Market Share by Application: 2023 VS 2030
Figure 7. Cancer Case Studies
Figure 8. Cardiovascular Case Studies
Figure 9. Central Nervous Systems Case Studies
Figure 10. Metabolic Disorders Case Studies
Figure 11. Gastrointestinal Disorders Case Studies
Figure 12. Dermatology Case Studies
Figure 13. Others Case Studies
Figure 14. Biosimilar Therapeutic Peptides Report Years Considered
Figure 15. Global Biosimilar Therapeutic Peptides Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Biosimilar Therapeutic Peptides Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Biosimilar Therapeutic Peptides Market Share by Region: 2023 VS 2030
Figure 18. Global Biosimilar Therapeutic Peptides Market Share by Players in 2023
Figure 19. Global Top Biosimilar Therapeutic Peptides Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Therapeutic Peptides as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Biosimilar Therapeutic Peptides Revenue in 2023
Figure 21. North America Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Biosimilar Therapeutic Peptides Market Share by Country (2019-2030)
Figure 23. United States Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Biosimilar Therapeutic Peptides Market Share by Country (2019-2030)
Figure 27. Germany Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Biosimilar Therapeutic Peptides Market Share by Region (2019-2030)
Figure 35. China Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Biosimilar Therapeutic Peptides Market Share by Country (2019-2030)
Figure 43. Mexico Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Biosimilar Therapeutic Peptides Market Share by Country (2019-2030)
Figure 47. Turkey Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Biosimilar Therapeutic Peptides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Pfizer Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 51. li Lilly and Company Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 52. Sanofi Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 53. Takeda Pharmaceuticals Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 54. Teva Pharmaceuticals Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 55. Amgen Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 56. AstraZeneca Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 57. Novartis AG Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 58. Novo Nordisk Revenue Growth Rate in Biosimilar Therapeutic Peptides Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
